…

PulseCath is proud sponsor at the upcoming EUMS-Conference in Hannover on 11 – 14 September 2024. The congress is going to become a Joint-EUMS-Mayo-Hannover-Heart-Conference. This partnership will facilitate…

We are grateful to announce Dr. Grzegorz Sobieszek, Head of the Department of Cardiology, as official proctor for PulseCath iVAC 2L – pVAD – Percutaneous Ventricular Assist Device,…

⚡️PulseCath expands in Asia-Pacific (APAC) region.⚡️In Hong Kong the first successful Complex High Risk and Indicated (CHIP) PCI case with the support of iVAC 2L, pulsatile percutaneous ventricular assist…

📢 Last week PulseCath closed a great EuroPCR again. As every year, great interest, many fruitful meetings, discussions and contacts. Some highligths: 🚩E-poster – Pulsatile mechanical circulatory support…

Excited to share some highlights from EuroPCR 2024 in Paris! Join us for sessions featuring iVAC 2L technology, pulsatile percutaneous ventricular assist device, for protected Complex Higher-risk Indicated…

We are thrilled to announce the first TEACH Course in the Center of Excellence for PulseCath iVAC 2L, pVAD – Percutaneous Ventricular Assist Device, in Italy hosted by…

🌟 The CEO Views is proud to recognize PulseCath, a medical device company as one of the ‘Top 50 Most Innovative Companies to Watch 2024’. The award felicitates…

🚀 We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Drs. Hatim Al-Lawati and Dr. Khalid Al-Saidi Royal…

We proudly announce the successful achievement of the transition from Medical Device Directive (MDD) CE marking to Medical Device Regulation (EU) 2017/745 (MDR) for our groundbreaking product, iVAC…